1492 Capital Management’s AbbVie ABBV Stock Holding History

1492 Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,340	Closed	-$217K	–	113
2022 Q1	$217K	Buy	+1,340	New	+$195K	0.12%	96

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

1492 Capital Management's ABBV Position: Q2 2022 in Review

1492 Capital Management sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,340 shares — an estimated $217K sold.

1492 Capital Management first reported a position in ABBV in Q1 2022 and held it in 1 quarter. The position peaked at $217K in Q1 2022. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

1492 Capital Management reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
1492 Capital Management sold 1,340 AbbVie shares in Q2 2022, an estimated $217K.
1492 Capital Management first reported a position in AbbVie in Q1 2022 and held it in 1 quarter.
1492 Capital Management's AbbVie position peaked at $217K in Q1 2022.
3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on 1492 Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.